Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports that JAK inhibitors were effective in inducing remission in ulcerative colitis patients and presented an acceptable safety profile with a range of manageable side effects.

This study found that in thin cutaneous melanomas, tumor regression is associated with a higher risk of sentinel lymph node involvement.

An arthritis drug helped a person with severe hair loss regrow their hair.

In this phase 3 trial, baricitinib showed effectiveness and safety in both adolescents and adults with severe alopecia areata, with adolescents achieving higher response rates despite more severe baseline conditions, suggesting the advantages of early treatment.

This abstract describes a program with various presentations and events focused on Canadian excellence in rheumatology but reports no new research findings.

This study found that treatment with ritlecitinib or brepocitinib was effective in improving scalp hair loss for patients with alopecia areata over 24 weeks compared to placebo.

This review discusses the discovery and potential therapeutic uses of proteasome inhibitors across various diseases, including cancer and autoimmune conditions, but does not present new clinical data.

This case study reports a 70-year-old man with treatment-resistant pityriasis rubra pilaris achieving complete clinical remission with ustekinumab, adding to evidence supporting biologic therapy when TNF inhibitors are unsuitable.

This study found that the monophasic oral contraceptive ethinylestradiol/chlormadinone acetate was more effective in treating mild to moderate papulopustular acne in women than ethinylestradiol/levonorgestrel.

This research highlights the potential of emulgel as an advanced topical drug delivery system, offering improved efficacy for hydrophobic medications in treating dermatological conditions and a range of ailments with its dual release control mechanism of gel and emulsion.

This study found that approximately 85% of adults with severe alopecia areata who responded to baricitinib at 52 weeks maintained their improvement over a span of four years.

This study found that Litfulo improved hair regrowth in patients aged 12 and older with severe alopecia areata but did not meaningfully improve anxiety or depression symptoms compared to placebo.

This study found that DEB-BACE combined with systemic chemotherapy was more effective than chemotherapy alone for unresectable lung squamous cell carcinoma, reducing side effects and improving survival rates.

This case study reports a successful use of co-trimoxazole in treating a 13-year-old girl with symptoms suggestive of autoimmune disorders and relapsing polychondritis.

Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.

In this case report, a 42-year-old woman with cutaneous dermatomyositis showed significant improvement, including reduction of erythema, pruritus, and scaling, after starting JAK inhibitor tofacitinib, especially when conventional systemic treatments failed and intravenous immune globulin wasn't viable.

This phase Ib study found that combining pegylated liposomal doxorubicin and pembrolizumab was well-tolerated and effective, with durable antitumor responses and a median survival of over two years in heavily pretreated ER-positive metastatic breast cancer patients.

This review describes the evolution of treatments for relapsing multiple sclerosis, highlighting that while newer potent monoclonal agents can potentially achieve disease remission, they also pose moderate to severe adverse event risks that healthcare providers must understand.

In this study, the researchers reported that the safety profile was similar across all DMARD treatment regimens for early rheumatoid arthritis, but the most severe side effects occurred in the leflunomide group.

In this report, a female patient with ulcerative colitis, alopecia areata, and pyoderma gangrenosum showed improvement in all three conditions after being treated with tofacitinib.

Baricitinib helps regrow hair in teens with severe alopecia areata.

This study documented successful use of Brevilin-A, a topical treatment, in pediatric patients with alopecia areata, indicating it as a potentially safe and effective option for managing mild-moderate cases and resistant forms of the disease.

This report discusses the FDA's rejection of Aveed, a long-acting testosterone injection, due to safety concerns despite divided advisory committee opinions, without presenting new clinical data.

This case report describes a young woman with ankylosing spondylitis who developed a severe paradoxical skin reaction after six months on certolizumab, requiring treatment with secukinumab and methotrexate.

This case report describes a 19-year-old patient with microsatellite stable adrenocortical carcinoma who showed a promising 36-month response to pembrolizumab, including structural and biochemical improvements, with primary adrenal insufficiency as a major side effect.

This study reports on a patient's case with support data available on request but provides no new research findings.

This review found that, among 103 patients treated off-label with abrocitinib for conditions beyond atopic dermatitis, favorable clinical outcomes were reported for most cases, except one isolated case involving erythematotelangiectatic rosacea.

This study found that the oral JAK inhibitors ritlecitinib and brepocitinib were effective in maintaining hair regrowth in alopecia areata with continuous use, though efficacy decreased after withdrawal.

This study, involving a retrospective analysis of 24 patients in France, found that paradoxical psoriasiform alopecic reactions on the scalp associated with TNFα-targeted therapies for inflammatory bowel disease are rare yet non-scarring, with all patients achieving complete hair regrowth within two months after treatment adjustments.